Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Juni 2013

Planlagt Fastgjort Låst Flyttet Genmab
505 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • investor1989I Offline
    investor1989I Offline
    investor1989
    wrote on sidst redigeret af
    #491

    http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf FDA update på BTD mv.

    1 Reply Last reply
    0
    • D Offline
      D Offline
      deleted-user
      wrote on sidst redigeret af
      #492

      spændende

      1 Reply Last reply
      0
      • P Offline
        P Offline
        Plextoren
        wrote on sidst redigeret af
        #493

        vil lige poste den her også: Bayer in $520 Million Pact With Seattle Genetics

        1 Reply Last reply
        0
        • P Offline
          P Offline
          Plextoren
          wrote on sidst redigeret af
          #494

          https://www.nordnet.dk/mux/web/analys/nyheter/visaNyhet.html?itemid=269125003&sourcecode=djn

          1 Reply Last reply
          0
          • J Offline
            J Offline
            JKY_VH
            wrote on sidst redigeret af
            #495

            Tak Plex, bestemt interessant

            1 Reply Last reply
            0
            • G Offline
              G Offline
              gentogen
              wrote on sidst redigeret af
              #496

              Dr. Janine Schuurman, Director Strategic Research at Genmab, will give a presentation on the efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange at the International Conference on monoclonal antibodies and cancer stem cells that will be held from 24th to the 26th June 2013

              1 Reply Last reply
              0
              • SolsenS Offline
                SolsenS Offline
                Solsen
                wrote on sidst redigeret af
                #497

                Link Preview Image
                The FDA's Cancer Czar Says He Can't Approve New Drugs Fast Enough

                Dr. Richard Pazdur Maybe more than any other person alive, Richard Pazdur, the director of the Food and Drug Administration's Office of Oncology and Hematology Products, personifies the tension between the need to get new drugs to patients fast and the competing desire to make sure they are safe and effective [...]

                favicon

                Forbes (www.forbes.com)

                1 Reply Last reply
                0
                • JørgenVarnæsJ Offline
                  JørgenVarnæsJ Offline
                  JørgenVarnæs
                  wrote on sidst redigeret af
                  #498

                  tak for den artikel solsen - jeg bed mærke i, at Pazdur specifikt nævnte Hazard Ratio som del af grunden til at afvise...

                  1 Reply Last reply
                  0
                  • G Offline
                    G Offline
                    gentogen
                    wrote on sidst redigeret af
                    #499

                    Ja, men det går vel bare på, at fimaet i sin ansøgning slet ikke havde regnet på nogen ratio

                    1 Reply Last reply
                    0
                    • MadsSkjernM Offline
                      MadsSkjernM Offline
                      MadsSkjern
                      wrote on sidst redigeret af
                      #500

                      Der bliver kamp til stregen på cd38 antistof markedet: http://www.reuters.com/article/2013/06/26/nj-morphosys-idUSnBw266538a+100+BSW20130626

                      1 Reply Last reply
                      0
                      • S Offline
                        S Offline
                        Sukkeralf
                        wrote on sidst redigeret af
                        #501

                        Har lige skrevet et indlæg om det - ja den er ikke god. Nok den værste partner for Genmab/Janssen

                        1 Reply Last reply
                        0
                        • L Offline
                          L Offline
                          lom
                          wrote on sidst redigeret af
                          #502

                          Jeg tænker nu at det er ok for GEN, da Janssen må speede op. Og som du skriver er "vi" et år foran. Man kan jo heller ikke forvente eller tro at de andre bare sidder med hænderne i skødet

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Sukkeralf
                            wrote on sidst redigeret af
                            #503

                            Det bedste ville jo være, hvis MOM202 ikke viste effekt, for så havde Genmab lavet noget virkelig unikt. Men konkurrence er jo ikke altid dårlig, så der kommer også gode ting ud af det.

                            1 Reply Last reply
                            0
                            • G Offline
                              G Offline
                              gentogen
                              wrote on sidst redigeret af
                              #504

                              Omvendt beviser det vel bare, at Daratumumab ses som den værste konkurrent af konkurrenten

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                Sukkeralf
                                wrote on sidst redigeret af
                                #505

                                Præcis

                                1 Reply Last reply
                                0
                                • J Offline
                                  J Offline
                                  JKY_VH
                                  wrote on sidst redigeret af
                                  #506

                                  God ide at Jyske Quant koncentrerer sig om charms i stedet for Genmab. Så kommer deres "ekspertise" til rette http://www.proinvestor.com/investornyt/69776/pandora-jyske-bank-haever-anbefaling-til-kob-opd

                                  1 Reply Last reply
                                  0

                                  Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                  Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                  With your input, this post could be even better 💗

                                  Tilmeld Log ind

                                  • Log ind

                                  • Har du ikke en konto? Tilmeld

                                  • Login or register to search.
                                  • First post
                                    Last post
                                  0
                                  • Debatforum
                                  • Seneste
                                  • Populære
                                  • Bruger